November 9, 2018 QUARTERLY REPORT – 2018 Q3
Posted at 10:00h
in Uncategorized
Vaccibody - Quarterly report 2018 Q3...
October 10, 2018 VACCIBODY UPDATES ON CANCER NEOANTIGEN PHASE I/IIA CLINICAL TRIAL: FIRST 10 PATIENTS ENROLLED, AND VACCINATIONS STARTED.
Posted at 12:00h
in Uncategorized
Vaccibody AS, a clinical stage immunotherapy company focused on developing personalized neoantigen cancer vaccines to target solid tumors, today announces that the first 10 patients have been enrolled in its phase I/IIa cancer neoantigen vaccine trial and that vaccinations with VB10.NEO have started. The trial...
September 26, 2018 Positive results from the 6-months Interim analysis of the phase IIa clinical study in high grade cervical dysplasia provides Proof-of-Concept for Vaccibody’s immunotherapy platform.
Posted at 10:00h
in Uncategorized
Vaccibody AS today announced positive 6-months interim results from the phase IIa part of the clinical study VB C-01. This study is a first human dose, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3)...
September 20, 2018 Vaccibody announces clinical collaboration agreement with Nektar Therapeutics for evaluation of Vaccibody’s personalized cancer neoantigen vaccine in combination with Nektar’s CD-122-biased agonist, NKTR-214
Posted at 10:00h
in Uncategorized
Vaccibody AS today announced a new clinical collaboration with Nektar Therapeutics to evaluate Vaccibody’s personalized cancer neoantigen vaccine, VB10.NEO, in combination with Nektar’s CD-122-biased agonist, NKTR-214. VB10.NEO is designed to specifically activate the patient’s immune system to tumour specific antigens, called neoantigens. NKTR-214 is designed to...
August 24, 2018 QUARTERLY REPORT – 2018 Q2
Posted at 10:00h
in Uncategorized
Vaccibody - Quarterly report 2018 Q2...
July 11, 2018 Annual Report 2017
Posted at 10:15h
in Uncategorized
Vaccibody - Annual report 2017...
May 14, 2018 QUARTERLY REPORT – 2018 Q1
Posted at 10:00h
in Uncategorized
Vaccibody - Quarterly report 2018 Q1...
April 26, 2018 VACCIBODY AS ANNOUNCES STRONG KILLER T CELL RESPONSES (CD8+) in VB10.16 VACCINATED PATIENTS FURTHER STRENGTHENING THE STRONG POTENTIAL OF THEIR VACCINE TECHNOLOGY PLATFORM; PRESENTING AT EUROPEAN NEOANTIGEN SUMMIT AMSTERDAM
Posted at 10:00h
in Uncategorized
Vaccibody AS, a clinical-stage company focused on developing cancer vaccines to target solid tumors, today announces clinical data demonstrating vaccine-induced killer T cell responses (CD8+) in patients in their clinical program to treat precancerous cervical intraepithelial neoplasia (CIN) 2/3 lesions (VB C-01). President and Chief...
April 4, 2018 VACCIBODY AS ANNOUNCES INFORMED CONSENT SIGNED BY FIRST PATIENT AND ENROLMENT PROCESS INITIATED IN THE CANCER NEOANTIGEN PHASE I/IIA CLINICAL TRIAL.
Posted at 12:00h
in Uncategorized
Vaccibody AS, a clinical stage immunotherapy company focused on developing personalized neoantigen cancer vaccines to target solid tumors, today announces informed consent signed by the first patient and enrolment process initiated in the clinical trial. The patient will be enrolled in Heidelberg, Germany at the...
April 3, 2018 Vaccibody calls for Annual General Meeting.
Posted at 08:28h
in Uncategorized
Vaccibody calls for Annual General Meeting to be held on April 10, 2018 at 10.00 AM in Forskningsparken, Oslo. Shareholders will receive the call documents electronically or by post. The call documents can also be downloaded here....